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ABSTRACT
Numerous extrahepatic manifestations have been reported in hepatitis C virus (HCV) infection, particularly mixed cryoglobulinemia (MC). 
MC generally responds to clearance of HCV under pegylated-interferon plus ribavirin treatment. New direct-acting antiviral agents have 
been licensed for HCV under different combinations but have not been studied in severe forms of MC. Here, we present a case report 
describing a life-threatening form of MC with multivisceral involvement, which was successfully treated with concomitant rituximab, 
sofosbuvir and simeprevir. In light of the rapid clinical remission associated with sustained virological response and the excellent side-effect 
profile, this treatment should be considered as a first-line therapy in severe forms of MC. 
LEARNING POINTS
• A life-threatening form of mixed cryoglobulinemia can occur in hepatitis C virus infection.
• Treatment with concomitant rituximab, sofosbuvir and simeprevir is one therapeutic option with an excellent side-effect profile.
• Despite clinical remission, cryoglobulinemia can remain detectable without clinical manifestations.
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INTRODUCTION
Hepatitis C virus (HCV) infection is major cause of morbidity and mortality, affecting about 160 million people worldwide. Chronic infection 
is associated with an increased risk of cirrhosis, hepatocellular carcinoma and extrahepatic manifestations. Numerous papers have 
documented the link between mixed cryoglobulinemia (MC) and HCV infection, which affects 80–90% of patients with MC. Moreover, 
cryoglobulins (CGs) are found in 25–50% of patients with chronic HCV infection[1]. MC can be asymptomatic or have a wide range of clinical 
presentations. In particular, patients may develop symptomatic MC-related small vessel vasculitis with cardiac involvement. Mild forms are 
commonly cured with antiviral agents only (i.e. combination therapy with interferon and ribavirin), while life-threatening forms may require 
specific immunosuppressive therapy in addition to antiviral treatment. Recently, first generation direct-acting antiviral agents (DAAs) 
providing higher sustained virological response (SVR) were approved in Europe. Thus, a new panel of more active DAAs (i.e. sofosbuvir, 
simeprevir, daclatasvir, ledipasvir) and interferon-free regimens generally consisting of two or three DAAs with or without ribavirin, are now 
available. Also, a recent study found that long-term clearance of HCV led to persistent resolution or marked improvement of MC, suggesting 
the need for highly effective antiviral drugs. Here we describe a rare form of severe MC with cardiac insufficiency, glomerulonephritis and 
polyneuropathy in a patient with HCV genotype 1b infection effectively treated with rituximab and an interferon-free combination of 
simeprevir and sofosbuvir. To our knowledge, this is the first report of a successful triple therapy for this rare life-threatening complication 
of HCV-related MC.
CASE PRESENTATION
A 48-year-old woman was admitted to our hospital for dyspnoea and clinical signs of cardiac insufficiency. She had HCV genotype 1b (no 
previous treatment) with MC and suffered from psychiatric disorders. Her complaints were progressive shortness of breath over the 
preceding week, polyarthralgia, chronic pain and loss of feeling in her feet. Tests revealed haemolytic anaemia, acute renal failure, a type 
II MC and high viral load (Table 1). Clinical examination and transthoracic echocardiography (TTE) were consistent with severe cardiac 
insufficiency with a left ventricular ejection fraction of 30%. Coronarography and cardiac magnetic resonance imaging did not revealed 
any other abnormalities. A kidney biopsy showed membranoproliferative glomerulonephritis with subendothelial deposits. A diagnosis of 
severe MC with cardiac, renal, neurological, articular and cutaneous involvement was made.The patient was therefore prescribed rituximab 
375 mg/m2 weekly for 4 weeks together with a combination of simeprevir and sofosbuvir given for 12 weeks. The patient’s weakness and 
arthralgia improved greatly within a week. No clinical complications were reported. Twelve weeks after the end of treatment, there was 
no detectable viral load and hepatic and kidney function had greatly improved (Table 1). TTE showed normalization of the left ventricular 
ejection fraction. After 1 year, the patient was still in clinical remission with SVR although the cryoglobulinemia was still detectable (0.2 g/l). 
At baseline
1 month after 
DAA+rituximab therapy
6-month follow-up
Heart failure (NYHA) Class IV Class II Complete Resolution
Asthenia Major weakness Marked Improvement Complete Resolution
Arthralgia Intermittent Stable Stable
AST 84 IU/ml 43 IU/ml 20 IU/ml
ALT 70 IU/ml 23 IU/ml 10 IU/ml
Creatinine 169 μmol/l 110 μmol/l 75 μmol/l
Proteinuria 4 g/24 h 1.2 g/24 h 0.1 g/24 h
FM 0.1 0.4
FS 8.3 kPa 4.6 kPa
Viral Load1 7 log10 IU/ml Undetectable Undetectable
Cryoglobulinemia 0.19 g/l 0.19 g/l 0.2 g/l
C4 1 mg/dl 2 mg/dl 2 mg/dl
RF Negative Negative Negative
IgM monoclonal 412 mg/dl 119 mg/dl 34 mg/dl
1Using the Abbott RealTime HCV assay.
AST: alanine aminotransferase; ALT: aspartate aminotransferase; 
FM: FibroMeter; FS: FibroScan; NYHA: New York Heart 
Association functional classification; RF: rheumatoid factor.
Table 1 Patient data at baseline and during follow-up.
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DISCUSSION
HCV-related MC may result in acute or progressive life-threatening organ damage with a mortality rate of 20–80%[2]. Much therapeutic 
progress has been made since the initial treatment of MC with interferon alpha in 1987 and the discovery that HCV was its main aetiological 
agent. Pegylated interferon-alpha (PEG-IFNα) combined with ribavirin improves overall MC clinical response and SVR in up to 60% 
of patients. Rituximab has been successfully used in MC. Several trials have shown that rituximab has better efficacy than conventional 
treatments[3] and that it seems to be safe in HCV patients, in contrast to patients with hepatitis B virus. Controlled clinical trials have also 
demonstrated that PEG-IFN/ribavirin plus rituximab compared to PEG-IFN/ribavirin alone resulted in better clinical remission and CG 
clearance; those Authors proposed the use of rituximab in patients with severe vasculitis, with or without plasmapheresis, before initiation 
of antiviral therapy. First-generation DAAs (boceprevir or telaprevir) in combination with PEG-IFNα and ribavirin have been shown to 
provide higher (up to 75%) SVR in HCV genotype 1. They have also been demonstrated to be very effective in MC[4] but with high rates 
of side effects. Since 2014, new DAAs with improved side effect profiles and SVR levels (>90%) have been approved. An interferon-free 
combination of daily sofosbuvir and simeprevir for 12 weeks was recently studied and validated by international recommendations[5] in 
patients with genotype 1 HCV. 
In the absence of other explanations, we attributed the cardiac insufficiency in our patient to MC, despite its rarity in this setting (less than 
5% of MC[2]). Cardiac involvement is associated with a poor survival rate[2]. Thus, in light of the association between glomerulonephritis 
and neuropathy, it was decided to institute a highly effective treatment targeting both autoimmunity and viral triggers. Plasmapheresis 
was not performed because of patient refusal. The psychiatric disorder contraindicated interferon, while ribavirin was ruled out because 
of risks associated with the haemolytic anaemia. Finally, rituximab was started after initial management of acute decompensated heart 
failure, together with daily sofosbuvir (400 mg) and simeprevir (150 mg) for 12 weeks. This combination has not been previously studied 
in severe forms of MC, as rituximab is generally started before antiviral treatment. Despite the life-threatening condition of our patient 
with severe cardiac and kidney involvement, this triple therapy of sofosbuvir, simeprevir and rituximab resulted in a spectacular, rapid and 
complete clinical recovery with normalization of cardiac function and virological response, without any side effects. This first description of 
an interferon-free combination of new DAAs with rituximab is particularly encouraging and could be proposed as a first-line treatment for 
severe HC-related MC.
